| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of clinical oncology 39 (36), 4073-4126, 2021 | 763 | 2021 |
| Systemic therapy for melanoma: ASCO guideline R Seth, H Messersmith, V Kaur, JM Kirkwood, R Kudchadkar, ... Journal of Clinical Oncology 38 (33), 3947-3970, 2020 | 247 | 2020 |
| Advanced prostate cancer: treatment advances and future directions U Swami, TR McFarland, R Nussenzveig, N Agarwal Trends in cancer 6 (8), 702-715, 2020 | 157 | 2020 |
| Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline BD Santomasso, LJ Nastoupil, S Adkins, C Lacchetti, BJ Schneider, ... Journal of clinical oncology 39 (35), 3978-3992, 2021 | 149 | 2021 |
| Eribulin—a review of preclinical and clinical studies U Swami, I Chaudhary, MH Ghalib, S Goel Critical reviews in oncology/hematology 81 (2), 163-184, 2012 | 95 | 2012 |
| Recent advances in the management of metastatic prostate cancer N Sayegh, U Swami, N Agarwal JCO Oncology Practice 18 (1), 45-55, 2022 | 89 | 2022 |
| Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis U Swami, S Goel, S Mani Current drug targets 14 (7), 777-797, 2013 | 79 | 2013 |
| Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement U Swami, RH Nussenzveig, B Haaland, N Agarwal Annals of translational medicine 7 (Suppl 1), 2019 | 77 | 2019 |
| Eribulin in cancer treatment U Swami, U Shah, S Goel Marine drugs 13 (8), 5016-5058, 2015 | 68 | 2015 |
| Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer U Swami, PI Velho, R Nussenzveig, J Chipman, VS Santos, S Erickson, ... European urology 78 (5), 652-656, 2020 | 63 | 2020 |
| Immune checkpoint inhibitors in prostate cancer S Venkatachalam, TR McFarland, N Agarwal, U Swami Cancers 13 (9), 2187, 2021 | 60 | 2021 |
| Advanced stage melanoma therapies: detailing the present and exploring the future C Luther, U Swami, J Zhang, M Milhem, Y Zakharia Critical reviews in oncology/hematology 133, 99-111, 2019 | 55 | 2019 |
| Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience U Swami, P Grivas, SK Pal, N Agarwal Cancer Treatment and Research Communications 27, 100325, 2021 | 37 | 2021 |
| Ipilimumab-induced hypophysitis, a single academic center experience T Snyders, D Chakos, U Swami, E Latour, Y Chen, M Fleseriu, M Milhem, ... Pituitary 22, 488-496, 2019 | 36 | 2019 |
| Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study Y Zakharia, V Monga, U Swami, AD Bossler, M Freesmeier, M Frees, ... Oncotarget 8 (51), 89182, 2017 | 32 | 2017 |
| Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States U Swami, JA Sinnott, B Haaland, N Sayegh, TR McFarland, N Tripathi, ... Cancers 13 (19), 4951, 2021 | 30 | 2021 |
| Harnessing DNA replication stress for novel cancer therapy H Zhu, U Swami, R Preet, J Zhang Genes 11 (9), 990, 2020 | 29 | 2020 |
| Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review A Greco, D Safi, U Swami, T Ginader, M Milhem, Y Zakharia Cancers 11 (12), 1950, 2019 | 26 | 2019 |
| Current status of intralesional agents in treatment of malignant melanoma M Zawit, U Swami, H Awada, J Arnouk, M Milhem, Y Zakharia Annals of translational medicine 9 (12), 2021 | 25 | 2021 |
| SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer U Swami, RP Graf, RH Nussenzveig, V Fisher, H Tukachinsky, ... Clinical Cancer Research 28 (22), 4917-4925, 2022 | 24 | 2022 |
